Replies to post #236848 on Biotech Values

[DewDiligence]

ABT at all-time high. The company's 2020 performance and 2021 guidance are simply astonishing.

ABT expects $6.5-7B of 2021 COVID-19 diagnostic revenue.

[DewDiligence]

ABT _sold_$2.2B_of_COVID-19_diagnostics_in_1Q21 (down from $2.4B in 4Q20):

https://abbott.mediaroom.com/2021-04-20-Abbott-Reports-First-Quarter-2021-Results

Non-GAAP EPS guidance for 2021 remains >=$5.00 (+37%, or more, relative to 2020).

1Q21 one-page graphic:
https://www.abbottinvestor.com/static-files/f172ced6-f814-490b-8e5c-3be152119058